Carcinoma of the Prostate: The Clinical Potential of Biological Markers Other Than Acid Phosphatase

  • M. R. G. Robinson
  • D. Daponte
  • A. Fryszman
  • C. Chandrasekaran
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


Carcinoma of the prostate is a slowly progressive disease which may be managed in many different ways. Treatment alternatives include no treatment, surgery, irradiation, endocrine therapy and cytotoxic chemotherapy. Diagnosis is easily achieved by rectal examination and biopsy, and scanning techniques are readily available for accurate clinical staging. The common osteosclerotic metastases are not, however, easily assessed for progression or regression and other marker lesions suitable for accurate measurement do not often occur, even in advanced progressive disease. Therefore a good biological tumour marker would be invaluable to aid the clinician monitor disease progression and the response to treatment and to assess new hormonal and chemotherapeutic regimes in phase II clinical trials. Although Huggins and Hodges (1) used plasma acid phosphatase as a marker for this tumour it has the disadvantage that it is rarely elevated in non-metastatic cancer and that in metastatic disease its sensitivity (percentage true positive elevations) as a marker is low. In addition during hormonal therapy disease progression is often not accompanied by rising plasma levels of this enzyme.


Prostatic Cancer Benign Prostatic Hyperplasia Bone Alkaline Phosphatase Creatinine Kinase Alkaline Phosphatase Isoenzyme 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. Huggins and C.U. Hodges, Studies on prostatic cancer: effect of castration, oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, Cancer Research 1:293 (1941).Google Scholar
  2. 2.
    H.A. Hornberger, S.A. Miller, and G.L. Jacob, Radioimmunoassay of Creatinine Kinase B — isoenzymes in serum of patients with azotemia, obstructive uropathy or carcinoma of the prostate or bladder, Clin. Chem. 26:1821 (1980).Google Scholar
  3. 3.
    L.M. Silvermann, G.B. Dormer, M.H. Zweig, A.C. Von Steirtegheim, and Z.A. Tokes, Creatinine Kinase BB: a new tumour associated marker, Clin. Chem. 25:1432 (1979).Google Scholar
  4. 4.
    R.A. Field, A.C. Von Steirtegheim, M.H. Zweig, G.W. Weinar, A.S. Narayana, and D.L. Witt, The presence of creatinine kinase BB isoenzyme in patients with prostatic carcinoma, Clin. Chem. Acta 100:267 (1980).CrossRefGoogle Scholar
  5. 5.
    T. Ishibi, The prognostic usefulness of serum lactic dehydrogenase and its fifth isoenzyme in carcinoma of the prostate, Int. Urol. Nephrol. 8:221 (1976).CrossRefGoogle Scholar
  6. 6.
    E. Maganto-Pavon, S. Isorna, J.A. Navajo-Guliudo, E.R. Darnial-Fernandez and J.A. Martinez-Pineiro, La aldolasa serica en el cancer prostatico, Acta Urol. Esp. 111:227 (1979).Google Scholar
  7. 7a.
    Z. Wajsman, T.M. Chu, D. Bross, J. Saroff, G.P. Murphy, D.E. Johnson, W.W. Scott, R.P. Gibson, G.R. Prout, and J.D. Schmidt, Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma, J. Urol. 119:244 (1978).PubMedGoogle Scholar
  8. 8.
    R.D. Kane and D.F. Paulson, Carcinoembryonic antigen as an adjunt to determination of clinical stage in prostatic cancer, Nat. Cancer. Inst. Mono. 49:231 (1978).Google Scholar
  9. 9.
    D.J. Prockop and K.I. Kivirikko, Relationship of hydroxyproline in urine to collagen metabolism, Ann. Int. Med. 66:1243 (1967).CrossRefGoogle Scholar
  10. 10.
    M.C. Bishop and G.J. Fellows, Urinary hydroxyproline excretion -a marker of bone metastases in prostatic carcinoma, Brit. J. Urol. 49:711 (1977).PubMedCrossRefGoogle Scholar
  11. 11.
    K.S. Webb and S.H. Lin, Urinary fibronectin, Invest. Urol. 17:401 (1980).PubMedGoogle Scholar
  12. 12.
    R.J. Ablin, W.A. Soanes, and M.J. Gander, Alterations of serum proteins in patients with prostatic cancer following cryo-prostatectomy, Abstr. Clin. Res. 20:882 (1972).Google Scholar
  13. 13.
    E.O. Gursel, M.R. Megalli, M.S. Roberts, and R.J. Veenema, The effects of cryotherapy on serum immunoglobulins on patients with prostatic cancer, S.I.U. Proc. 16th Congress 2:256 (1973).Google Scholar
  14. 14.
    R. Lockwood, M. Sukhia, R.M. Basu, M.C. Stewardson, J. Sheard, and M.R.G. Robinson, Serum immunoglobulins before and during oestrogen treatment of carcinoma of the prostate, unpublished data.Google Scholar
  15. 15.
    F.A. Deture, L. Deardourff, A.G. Kauffman, and Y.M. Centifanto, A comparison of serum immunoglobulins from patients with nonneoplastic prostate and prostatic carcinoma, J. Urol. 120:435 (1978).PubMedGoogle Scholar
  16. 16.
    U.S. Seal, R.P. Doe, D.P. Byar, D.K. Corle, and the Veterans Administration Co-operative Urological Research Group, Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pre-treatment values to mortality in patients with prostatic cancer, Cancer 38:1108 (1976).PubMedCrossRefGoogle Scholar
  17. 17.
    A. Milford-Ward, E.H. Cooper, and A.L. Haughton, Acute phase reactant proteins in prostatic cancer, Brit. J. Urol. 49:411 (1977).CrossRefGoogle Scholar
  18. 18.
    C.B. Laurell, S. Kullander, and J. Thorell, Effect of combined estrogen-progestin contraceptive on the levels of individual plasma proteins, Scand. J. Clin. Lab. Invest. 21:337 (1968).PubMedCrossRefGoogle Scholar
  19. 19.
    K. Trautner, E.H. Cooper, S. Howarth, and A. Milford Ward, An evaluation of serum protein profiles in the long term surveillance of prostatic cancer, Scand. J. Urol. Nephrol. 14:143 (1980).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • M. R. G. Robinson
    • 1
  • D. Daponte
    • 1
  • A. Fryszman
    • 1
  • C. Chandrasekaran
    • 1
  1. 1.The General InfirmaryPontefractUK

Personalised recommendations